BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1

• 

  Register: Bridging Formulation & Device: Integrated Supply Chain Strategies for US Pharma Manufacturing

  Join us for a high-level discussion on overcoming pharmaceutical supply chain challenges through end-to-end integration.

  August 1, 2025
• 

  Layoffs

  Merck’s $3B Savings Push Claims 6,000 Jobs

  Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth areas of its business.

  August 1, 2025

   · 

  1 min read

   · 

  Tristan Manalac
• 

  Earnings

  ‘Very Impressive’ Amvuttra ATTR-CM Sales Send Alnylam Soaring

  In its first commercial quarter for ATTR-cardiomyopathy, Alnylam’s Amvuttra reached roughly 1,400 patients and made more than $490 million.

  August 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  FDA

  After Prasad’s Ouster, Makary Looks for Better Drug, Biologic Alignment at FDA

  The FDA has denied that it plans to combine the Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research into one entity.

  August 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• 

  Layoff Tracker

  Moderna Cutting 10% of Workforce Globally

  Follow along as BioSpace tracks job cuts and restructuring initiatives throughout 2025.

  August 1, 2025

   · 

  172 min read

   · 

  BioSpace Editorial Staff
• 

  Earnings

  Moderna’s Bancel Nay on M&A, Yay on R&D Partnerships

  It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough programs on its hands.

  August 1, 2025

   · 

  4 min read

   · 

  Annalee Armstrong
• 

  Patents

  Moderna Wins UK Patent Battle Against Pfizer and BioNTech

  A U.K. Court of Appeals ruling confirms the validity of a patent covering modifications of mRNA used in Moderna’s vaccines.

  August 1, 2025

   · 

  2 min read

   · 

  Dan Samorodnitsky
• 

  Earnings

  Regulatory Roadblocks Blemish Regeneron’s Otherwise Strong Q2

  Delays in the decision dates for high-dose Eylea are linked to issues at a Catalent-owned facility. Once these are resolved, Regeneron expects “to receive favorable action” on these applications, CEO Leonard Schleifer told investors.

  August 1, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  Zenara Pharma Receives U.S. FDA Approval for First Generic of Sertraline Hydrochloride Capsules with 180-Day CGT Exclusivity

  August 1, 2025

   · 

  2 min read
• Press Releases

  Bio-Rad Reports Second-Quarter 2025 Financial Results

  August 1, 2025

   · 

  23 min read